Rita K. Schmutzler

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · Journal of Clinical Oncology · 2014 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores

Bjarni J. Vilhjálmsson, Jian Yang, Hilary K. Finucane et al. · The American Journal of Human Genetics · 2015 · 1.5K citations · Full text

Public Health, Bioinformatics, Biostatistics +17

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Susan M. Domchek, Carol Aghajanian, Ronnie Shapira‐Frommer et al. · Gynecologic Oncology · 2015 · 300 citations · Full text

Medicine, Gynecology, Oncology +17

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Sibylle Loibl, Karsten E. Weber, Kirsten M. Timms et al. · Annals of Oncology · 2018 · 300 citations · Full text

Medicine, Oncology, Pharmacology +17